Session XXIII: Colorectal Cancer: Metastatic Disease

Saturday, July 1, 2023

09:30 – 13:15 CEST

Location:Auditorium A, Level 0

Chair(s)

Michel Ducreux, MD, PhD

Gustave Roussy, Université Paris-Saclay
Paris, France
Eric Van Cutsem, MD, PhD

University Hospitals Leuven / KU Leuven
Leuven, Belgium

Presentations:

09:30 – 09:40 CEST

LBA-5: Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study
Abstract Presenter: Akihito Kawazoe
09:40 – 09:50 CEST

Highlight Presentation of ASCO 2023 - Promising HER-2 Targeted Therapy
Speaker: Takayuki Yoshino, MD, PhD – National Cancer Center Hospital East, Japan
09:50 – 09:55 CEST

Colorectal Cancer Management Across Different Continents: Asian Guidelines
Speaker: Takayuki Yoshino, MD, PhD – National Cancer Center Hospital East, Japan
09:55 – 10:00 CEST

Colorectal Cancer Management Across Different Continents: ESMO Guidelines
Speaker: Andrés Cervantes, MD, PhD – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia
10:00 – 10:05 CEST

Colorectal Cancer Management Across Different Continents: NCCN Guidelines
Speaker: Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center
10:05 – 10:25 CEST

Colorectal Cancer Management Across Different Continents: Q&A and Panel Discussion
Chair: Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay
Chair: Eric Van Cutsem, MD, PhD – University Hospitals Leuven / KU Leuven
Panelist: Andrés Cervantes, MD, PhD – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia
Panelist: Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center
Panelist: Takayuki Yoshino, MD, PhD – National Cancer Center Hospital East, Japan
10:25 – 10:33 CEST

SO-32: Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT).
Abstract Presenter: Marco Germani
10:33 – 10:41 CEST

SO-33: The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – a post-hoc exploratory analysis of the randomized NORDIC9-study
Abstract Presenter: Gabor Liposits, MD – Department of Clinical Research, University of Southern Denmark
10:41 – 11:00 CEST

Checkpoint Inhibitors in MSI-H Colorectal Cancer
Speaker: Kristen K. Ciombor, MD, MSCI – Vanderbilt-Ingram Cancer Center
11:00 – 11:20 CEST

How to Make MSS Tumors More Sensitive for Immunotherapy?
Speaker: Josep Tabernero, MD – Vall d’Hebron University Hospital
11:20 – 11:40 CEST

BRAF Mutant Tumors: Strategy and New Data
Speaker: Erika Martinelli, MD, PhD – Università degli Studi della Campania Luigi Vanvitelli
12:10 – 12:45 CEST

Keynote Lecture: Early-Onset CRC
Keynote Speaker: Irit Ben-Aharon, MD, PhD – Rambam Health Care Campus
12:45 – 12:55 CEST

O-11: The genomic landscape of appendiceal adenocarcinoma revealed by 855 Whole Exome Sequences
Abstract Presenter: Michael White
12:55 – 13:05 CEST

O-12: NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal
Abstract Presenter: Van Morris, MD – MD Anderson Cancer Center
13:05 – 13:15 CEST

Discussant: O-11, O-12
Discussant: Juan Manuel O'Connor, MD, MSc – Instituto Alexander Fleming